Cover Image
市場調查報告書

麴菌症:開發中產品分析

Aspergillosis - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 232851
出版日期 內容資訊 英文 101 Pages
訂單完成後即時交付
價格
Back to Top
麴菌症:開發中產品分析 Aspergillosis - Pipeline Review, H1 2017
出版日期: 2017年05月23日 內容資訊: 英文 101 Pages
簡介

麴菌症是麴菌造成的感染或過敏反應。其症狀有咳嗽、發燒、頭痛、倦怠感、體重減輕及胸部疼痛等。這個疾病的致病風險因素有自體免疫系統衰弱或白血球減少、氣喘、長期皮質類固醇治療等。

本報告提供全球麴菌症治療藥的開發中產品概要,提供產品開發,上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

簡介

  • 調查範圍

麴菌症概要

治療藥的開發

  • 開發中產品的概要
  • 各企業的開發平台
  • 大學/研究機關所開發的開發平台
  • 企業開發中的產品
  • 大學/研究機關開發中的產品

治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

麴菌症的治療藥開發企業

  • Amplyx Pharmaceuticals Inc
  • Astellas Pharma Inc
  • Biomar Microbial Technologies
  • Biosergen AS
  • Cidara Therapeutics Inc
  • F2G Ltd
  • Hsiri Therapeutics LLC
  • iCo Therapeutics Inc.
  • Matinas BioPharma Holdings Inc
  • Merck & Co Inc
  • Nanomerics Ltd
  • Novabiotics Ltd
  • Pulmatrix Inc
  • Pulmocide Ltd
  • Scynexis Inc
  • Sealife PHARMA GMBH
  • Sigma-Tau SpA
  • Vical Inc
  • Visterra Inc

藥物簡介

麴菌症:暫停中的計劃

麴菌症:開發中止的產品

麴菌症:產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9341IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Aspergillosis - Pipeline Review, H1 2017, provides an overview of the Aspergillosis (Infectious Disease) pipeline landscape.

Aspergillosis is an infection or allergic response due to the Aspergillus fungus. Symptoms include cough, fever, headaches, general ill feeling (malaise), weight loss and chest pain. The predisposing factors include weakened immune system, low white blood cell level, asthma and long-term corticosteroid therapy. Treatment includes oral corticosteroids, antifungal and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Aspergillosis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Aspergillosis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Aspergillosis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Aspergillosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 2, 5, 19 and 2 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 2 and 3 molecules, respectively.

Aspergillosis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Aspergillosis (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Aspergillosis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Aspergillosis (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Aspergillosis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Aspergillosis (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Aspergillosis (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Aspergillosis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Aspergillosis - Overview
    • Aspergillosis - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Aspergillosis - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Aspergillosis - Companies Involved in Therapeutics Development
    • Amplyx Pharmaceuticals Inc
    • Astellas Pharma Inc
    • Biomar Microbial Technologies
    • Biosergen AS
    • Cidara Therapeutics Inc
    • F2G Ltd
    • Hsiri Therapeutics LLC
    • iCo Therapeutics Inc.
    • Matinas BioPharma Holdings Inc
    • Merck & Co Inc
    • Nanomerics Ltd
    • Novabiotics Ltd
    • Pulmatrix Inc
    • Pulmocide Ltd
    • Scynexis Inc
    • Sealife PHARMA GMBH
    • Sigma-Tau SpA
    • Vical Inc
    • Visterra Inc
  • Aspergillosis - Drug Profiles
    • amphotericin B - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • amphotericin B - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • amphotericin B - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • amphotericin B - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Amphotericin B sodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • APX-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • APX-001A - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ASP-9726 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Aspergillus fumigatus vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BSG-005 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • C-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • C-016 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CD-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • celastrol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellullar Immunotherapy for Viral Infections and Fungal Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • F-901318 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • itraconazole - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KB-425796C - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MDN-0018 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NP-339 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PC-945 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • posaconazole - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PTX-3 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SCY-078 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SLP-0901 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SLP-0904 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Aspergillosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Aspergillosis and Candidiasis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Fungal Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Fungal Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Invasive Aspergillosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine to Target Glucosylceramide for Fungal Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VIS-FNG - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VL-2397 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Aspergillosis - Dormant Projects
  • Aspergillosis - Discontinued Products
  • Aspergillosis - Product Development Milestones
    • Featured News & Press Releases
      • May 02, 2017: Vical Highlights Successful Outcome of Phase 1 Trial of VL-2397 Novel Antifungal During its Research and Development Day
      • Apr 25, 2017: Cidara Therapeutics Announces Promotion of Taylor Sandison, M.D., M.P.H., to Chief Medical Officer
      • Apr 17, 2017: Cidara Therapeutics to Present Data on Novel Antifungal CD101 at ECCMID and SID Annual Meetings
      • Jan 09, 2017: F2G Receives European Orphan Drug Designation for its Lead Candidate F901318
      • Dec 13, 2016: SCYNEXIS Achieves New Development Milestones Reinforcing the Versatility of SCY-078 in Treating Serious Fungal Infections
      • Nov 28, 2016: Cidara Therapeutics' Presentations at ASH 2016 to Highlight Potential Role of Novel Antifungal CD101 in Patients with Hematologic Malignancies
      • Nov 16, 2016: FDA Grants Orphan Drug Designation to Amplyx Pharmaceuticals for APX001 for Treatment of Multiple Invasive Fungal and Mold Infections
      • Oct 26, 2016: F2G Announces Publication of Initial F901318 Data in Scientific Journal PNAS
      • Sep 12, 2016: Amplyx Pharmaceuticals Initiates Dosing in Phase 1 Clinical Trial of APX001, a Novel Antifungal Product Candidate for Treatment of Life-Threatening Infections
      • Aug 24, 2016: SCYNEXIS Receives Orphan Drug Designation for SCY-078 for the Treatment of Invasive Aspergillus Infections
      • Jun 16, 2016: Antifungal work lands SBU professor $6 million from NIH
      • Jun 14, 2016: Amplyx Pharmaceuticals Announces Qualified Infectious Disease Product Designation for APX001 in Three Life-threatening Fungal Infections
      • May 24, 2016: Amplyx Pharmaceuticals Appoints Paul C. Grint, M.D., to Board of Directors
      • Mar 30, 2016: FDA Grants Vical Fast Track Designation for VL-2397 for the Treatment of Invasive Aspergillosis
      • Mar 07, 2016: Vical Initiates Phase 1 Trial of Novel Antifungal Compound VL-2397
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Aspergillosis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Aspergillosis - Pipeline by Amplyx Pharmaceuticals Inc, H1 2017
  • Aspergillosis - Pipeline by Astellas Pharma Inc, H1 2017
  • Aspergillosis - Pipeline by Biomar Microbial Technologies, H1 2017
  • Aspergillosis - Pipeline by Biosergen AS, H1 2017
  • Aspergillosis - Pipeline by Cidara Therapeutics Inc, H1 2017
  • Aspergillosis - Pipeline by F2G Ltd, H1 2017
  • Aspergillosis - Pipeline by Hsiri Therapeutics LLC, H1 2017
  • Aspergillosis - Pipeline by iCo Therapeutics Inc., H1 2017
  • Aspergillosis - Pipeline by Matinas BioPharma Holdings Inc, H1 2017
  • Aspergillosis - Pipeline by Merck & Co Inc, H1 2017
  • Aspergillosis - Pipeline by Nanomerics Ltd, H1 2017
  • Aspergillosis - Pipeline by Novabiotics Ltd, H1 2017
  • Aspergillosis - Pipeline by Pulmatrix Inc, H1 2017
  • Aspergillosis - Pipeline by Pulmocide Ltd, H1 2017
  • Aspergillosis - Pipeline by Scynexis Inc, H1 2017
  • Aspergillosis - Pipeline by Sealife PHARMA GMBH, H1 2017
  • Aspergillosis - Pipeline by Sigma-Tau SpA, H1 2017
  • Aspergillosis - Pipeline by Vical Inc, H1 2017
  • Aspergillosis - Pipeline by Visterra Inc, H1 2017
  • Aspergillosis - Dormant Projects, H1 2017
  • Aspergillosis - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Aspergillosis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top